Table 5.
Summary of BSEP and MDR3 In Vitro Transport Inhibition and DILI Assessment for the Aleo et al. (2017) Dataset (Using IC50 cutoff < 50 μM to Define BSEP and MDR3 Inhibitors)
| Criteria | % of Drugs With DILI Predicted Correctly, PPV | % of DILI Missing in the Prediction, FNR | % of DILI Predicted Accurately, ACC (n = 119) |
|---|---|---|---|
| BSEP inhibitor | 73.9% | 75.4% | 51.3% |
| MDR3 inhibitor | 57.6% | 44.9% | 50.4% |
| BDDCS class 2 | 87.2% | 50.7% | 66.4% |
| Cmax, total > 1 μM | 75.7% | 18.8% | 73.9% |
| BDDCS class 2 + Cmax, total > 1 μM | 93.9% | 55.1% | 66.4% |
| BSEP and MDR3 inhibitor | 77.8% | 79.7% | 50.4% |
| BSEP and MDR3 + Cmax, total > 1 μM | 100.0% | 79.7% | 53.8% |